Corbus Pharmaceuticals Reports 2016 First Quarter Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Corbus Pharmaceuticals Reports 2016 First Quarter Financial Results and Provides Business Update

NORWOOD, MA --(Marketwired - May 16, 2016) - Corbus Pharmaceuticals Holdings, Inc.  ( NASDAQ : CRBP ) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today its financial results for the first quarter ended March 31, 2016.

The Company also provided an update on its corporate progress and the clinical status and anticipated milestones for Resunab , its novel synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrosis. Resunab is currently being evaluated in three separate Phase 2 clinical studies in cystic fibrosis ('CF"), diffuse cutaneous systemic sclerosis ("systemic sclerosis"), and skin-predominant dermatomyositis and plans to initiate a clinical study in systemic lupus erythematosus ("SLE") in the first quarter of 2017.

Recent Corporate Highlights

"We continue to advance our clinical and regulatory strategies forward, paving the way for key clinical data readouts starting in the fourth quarter of this year," stated Yuval Cohen, Ph.D., Chief Executive Officer of the Company.

Expected Near-Term Milestones

  • Complete patient enrollment in the U.S. Phase 2 Clinical study for systemic sclerosis;
  • Complete patient enrollment in the Phase 2 clinical study for CF;
  • Obtain Orphan Drug Designation in Europe for the treatment of both CF and systemic sclerosis;
  • Report top-line safety and efficacy data of Phase 2 clinical studies for systemic sclerosis and CF in Q4 2016;
  • Commence the open-label extension study in systemic sclerosis;
  • Continue to advance the Phase 2 clinical study in dermatomyositis, which is expected to be completed in the first quarter of 2017;
  • Complete preparation for the launch of the Phase 2 clinical study in adults with SLE, which is expected to launch in the first quarter of 2017;
  • Conduct additional mechanism of action studies with Resunab in relevant pre-clinical models; and
  • Participate in scientific conferences throughout 2016, including the European Cystic Fibrosis Society Conference, the North American Cystic Fibrosis Conference and the American College of Rheumatology Annual Meeting.

"Corbus' mission is to develop novel drugs that engage the immune system to treat rare and uncommon life-threatening diseases that have clear unmet medical needs. This is underscored by our ongoing Phase 2 clinical studies of Resunab in three rare inflammatory diseases with significant unmet needs and the expansion into our fourth indication in the first quarter of next year. Our longer-term business strategy is to expand our pipeline with additional assets while maintaining our focus on these rare inflammatory indications," concluded Dr. Cohen.

Summary of Financial Results for First Quarter 2016

For the quarter ended March 31, 2016, the Company reported a net loss of approximately $2,892,000 or a net loss per diluted share of $0.08, compared to a net loss of approximately $1,536,000, or a net loss per diluted share of $0.06 for the quarter ended March 31, 2015. The increase in the net loss for the quarter ended March 31, 2016 is attributable to expenses related to our clinical studies for systemic sclerosis and CF, and increased staffing costs. The Company ended the quarter with approximately $9,688,000 of cash and cash equivalents and the Company has the potential to receive $2.5 million in additional milestone payments under its development award with the Cystic Fibrosis Foundation Therapeutics, Inc.

About Resunab

Resunab is a novel synthetic oral endocannabinoid-mimetic drug that preferentially binds to the CB2 receptor expressed on activated immune cells and fibroblasts. CB2 activation triggers endogenous pathways that resolve inflammation and halt fibrosis. Preclinical and Phase 1 studies have shown Resunab to have a favorable safety, tolerability and pharmacokinetic profile. It has also demonstrated promising potency in preclinical models of inflammation and fibrosis. Resunab is designed to trigger the production of "Specialized Pro-resolving Lipid Mediators" that activate an endogenous cascade responsible for the resolution of inflammation and fibrosis, while reducing production of pro-inflammatory eicosanoids and cytokines. Resunab has direct effects on fibroblasts to halt tissue scarring. In effect, Resunab triggers endogenous pathways to turn "off" chronic inflammation and fibrotic processes, without causing immunosuppression.

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Our lead product candidate, Resunab, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation, and fibrotic processes. Resunab is currently in Phase 2 clinical studies for the treatment of cystic fibrosis, diffuse cutaneous systemic sclerosis, skin-predominant dermatomyositis and systemic lupus erythematosus.

For more information, please visit www.CorbusPharma.com and connect with the Company on Twitter , LinkedIn , Google+ and Facebook .

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Corbus Pharmaceuticals Holdings, Inc.  
Condensed Consolidated Statements of Operations  
(Unaudited)  
   
    For the Three Months Ended  
    March 31,  
    2016     2015  
Collaboration revenue   $ 396,598     $ -  
Operating expenses:                
  Research and development     2,173,933       723,430  
  General and administrative     1,109,889       811,869  
    Total operating expenses     3,283,822       1,535,299  
Operating loss     (2,887,224 )     (1,535,299 )
Other income (expense):                
  Interest expense     (6,430 )     (979 )
  Interest income     1,070       560  
  Foreign currency exchange gain     343       -  
    Other expense, net     (5,017 )     (419 )
Net loss   $ (2,892,241 )   $ (1,535,718 )
Net loss per share, basic and diluted   $ (0.08 )   $ (0.06 )
Weighted average number of common shares outstanding, basic and diluted     37,605,210       25,871,796  
             
             
Corbus Pharmaceuticals Holdings, Inc.  
Condensed Consolidated Balance Sheets  
             
    March 31, 2016 (Unaudited)     December 31, 2015  
ASSETS                
Current assets:                
  Cash and cash equivalents   $ 9,687,805     $ 12,338,275  
  Prepaid expenses     474,560       376,515  
    Total current assets     10,162,365       12,714,790  
Restricted cash     36,375       36,375  
Property and equipment, net     296,534       124,138  
      Total assets   $ 10,495,274     $ 12,875,303  
LIABILITIES AND STOCKHOLDERS' EQUITY                
Current liabilities:                
  Notes payable   $ 92,958     $ 162,019  
  Accounts payable     1,230,449       1,314,377  
  Accrued expenses     1,297,988       562,279  
  Deferred revenue, current     1,455,020       1,591,358  
    Total current liabilities     4,076,415       3,630,033  
Deferred revenue, noncurrent     -       260,260  
Other long-term liabilities     14,852       -  
      Total liabilities     4,091,267       3,890,293  
Commitments and Contingencies                
Stockholders' equity                
  Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding at March 31, 2016 and December 31, 2015     -       -  
  Common stock, $0.0001 par value; 150,000,000 shares authorized, 37,605,827 and 37,605,134 shares issued and outstanding at March 31, 2016 and December 31, 2015     3,761       3,761  
  Additional paid-in capital     22,570,301       22,259,063  
  Accumulated deficit     (16,170,055 )     (13,277,814 )
    Total stockholders' equity     6,404,007       8,985,010  
      Total liabilities and stockholders' equity   $ 10,495,274     $ 12,875,303  
                 
                 

Investor Contact Jenene Thomas Jenene Thomas Communications, LLC Phone: +1 (908) 938-1475 Email: jenene@jenenethomascommunications.com Media Contact David Schull Russo Partners, LLC Phone: +1 (858) 717-2310 Email: david.schull@russopartnersllc.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 33

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
Dar Global Expands Jeddah Portfolio with $267M Project

Updated Category News Views 221

Dar Global's Big Jeddah Move: A $267M Bet Alright, let's dive into what Dar Global's been up to in Saudi Arabia. They've just announced a whopping SAR 1 billion development project in Jeddah, bringing an international luxury brand to the city with an exclusive co-branded residential concept. Now that's something to chew on for any investor eyeing the Middle East's real...

Continue Reading
Salvation Army’s Angel Tree: 2026 Holiday Cheer Drive

Updated Category News Views 100

Kickstarting Holiday Generosity: The Angel Tree Program Man, there's something heartwarming about a Christmas that shines bright for everyone. The Salvation Army's Angel Tree program is back for another season, rolling up with a mission to spark joy across the country. For over 45 years now, this initiative's been the answer to many Christmas wish lists, especially for...

Continue Reading
S&P Global's Bold $2 Billion Debt Offering Details

Updated Category News Views 80

Drilling Down into S&P Global's Debt Move S&P Global's throwing its hat in the ring with a colossal $2 billion debt offering. Now, they aren't just setting it on the table — they're notably carving it up into three chunks. You’ve got $750 million at 5.600% that comes due in 2031, $600 million at 5.800% for 2034, and $650 million at a 6.000% rate maturing in 2036....

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 137

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
Orangetheory Adds NASM Training for Coaching Edge

Updated Category News Views 78

A Shift in Coaching Standards Ever seen a fitness brand tilt towards a change so fast it leaves you slack-jawed? Well, here we go with Orangetheory Fitness pushing its chips all in with NASM-certified coaches geared for the GLP-1 era. A bold move? Sure, but they aim to become trendsetters instead of just another player in the fitness game. The Impact of NASM Certification...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 207

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
China's APEC Summit: A Catalyst for Business Growth?

Updated Category News Views 135

A Shift Toward Regional Stability China's position as this year's APEC rotating chair presents both opportunity and challenge as economies grapple with trade barriers and technological upheaval. The 33rd APEC Economic Leaders' Meeting in Shenzhen is intended to navigate these turbulent waters, setting the stage for a more stable regional environment. APEC's Role in...

Continue Reading
Ontario Airport Braces for Holiday Travel Surge

Updated Category News Views 92

Gearing Up for a Thanksgiving Travel Boom Think Thanksgiving brings only turkey to the table? Down in Ontario, California, it's all about jet fuel and passenger counts. The Ontario International Airport (ONT) is where the skies are buzzing, forecasting over 227,000 passengers trying to soak up the holiday vibes by air. Compare that to the numbers when the local folks...

Continue Reading
LongueVue Capital: Betting Big on Sports & Entertainment

Updated Category News Views 90

LongueVue Capital's Bold Move You don’t always hear about private equity firms diving head-first into the sports and entertainment sector, but LongueVue Capital (LVC) is doing just that. This New Orleans-based firm is shifting its gears and setting sights on founder-owned ventures crucial to these industries. They’re asking the key question: Why focus on just the...

Continue Reading

Top 5 Most Recently Viewed Articles

Insights on Oy Rosaco Ab's Recent Transactions in Rapala VMC

Updated Category News Views 159

Understanding Recent Transactions by Oy Rosaco Ab Rapala VMC Corporation, known for its prominent role in the fishing tackle industry, recently experienced noteworthy managerial transactions attributed to Oy Rosaco Ab. These transactions, which occurred on a specific date, highlight the financial activities that often play a vital role in influencing stock decisions and...

Continue Reading
Altria's Board Welcomes Richard S. Stoddart as New Director

Updated Category News Views 219

Richard S. Stoddart Joins Altria’s Board of Directors Altria Group, Inc. (NYSE: MO) has made an exciting announcement regarding the expansion of its Board of Directors. The company is pleased to welcome Richard S. Stoddart, who will officially join the board soon. His significant background in leadership roles across various sectors will be a valuable addition as Altria...

Continue Reading
Exploring the Growth of Modular Building Systems Market

Updated Category News Views 220

Understanding the Rise of Panelized Modular Building Systems The panelized modular building systems market is on a remarkable trajectory, projected to grow significantly over the next few years. With a forecasted increase of around USD 47.7 billion driven by technological advancements and the quest for cost efficiency, this market is becoming a focal point for the...

Continue Reading
Inspire Veterinary Partners Faces Stock Decline and Strategic Moves

Updated Category News Views 141

Inspire Veterinary Partners Hits a 52-Week Low Inspire Veterinary Partners has found itself in a precarious position as its stock price has plunged to a troubling 52-week low of $0.23. This significant drop, amounting to a staggering 99.76% decline over the past year, has sent ripples of concern among its investors. As the company struggles amid market challenges and...

Continue Reading
Collaborative Initiatives in STEM Education Introduced

Updated Category News Views 117

Pitsco Education Partners with Study Smart Tutors Pitsco Education and Study Smart Tutors have announced a strategic partnership aimed at enhancing STEM education across various learning environments. This collaboration seeks to integrate the strengths of both organizations, providing educators and students with unique resources and opportunities. By combining Pitsco's...

Continue Reading